Prevalence of BCR-ABL Gene Fusions in Patients with Chronic Myeloid Leukemia with Multiplex Reverse Transcription Polymerase Chain Reaction

Document Type : Original Article (s)

Authors

1 Department of Biology, School of Basic Sciences, Islamic Azad University, Urmia Branch, Urmia ,Iran

2 Department of Biology, School of Basic Sciences, Islamic Azad University, Damghan Branch, Damghan,Iran

Abstract

Background: Chronic myeloid leukemia (CML) is a clonal malignancy of hematopoietic stem cells. Type of fusion in these patients can be clinically significant and help to better understand the pathogenesis of leukemic cells with t (9:22). The aim of this study is to check BCR-ABL mutations and determine the prevalence of various gene fusions using reverse transcription polymerase chain reaction (RT-PCR) method in patients with CML.Methods: After making sure of having the disease and signing the written consent, 5-8 ml blood was taken from patients with aseptic technique. After RNA extraction, blood samples were centrifuged to separate mononuclear cells (MNCs) and complete RNA was extracted. Multiplex reaction PCR was carried out in 35 cycles.Findings: All 40 patients were positive in terms of BCR-ABL fusions. Of them 21 persons (52.5%) had b3a2 fusion and 16 persons (38.88%) with b2a2 fusion and finally 3 persons with ale2 fusion.Conclusion: Uniformity of reaction products and the results obtained in this study showed that RT-PCR method is feasible as a fast, sensitive and safe method to determine the prevalence of BCR-ABL genes in the sampling of peripheral blood. Also, the difference in the rate of fusion due to racial differences in the population can be studied.

Keywords

References

  1. Inukai T, Sugita K, Suzuki T, Ijima K, Goi K, Tezuka T, et al. A novel 203 kD aberrant BCR-ABL product in a girl with Philadelphia chromosome positive acute lymphoblastic leukaemia. Br J Haematol 1993; 85(4): 823-5.
  2. Bain BJ, Clark DM, Wilkins BS. Bone Marrow Pathology. 4th ed. Oxford, UK: Wiley-Blackwell; 2010.
  3. Lichtman MA, Williams WS. Williams Hematology. 7th ed. New York, NY: McGraw-Hill; 2006. p. 1264-70.
  4. American Cancer Society. Cancer facts and figures 2007 [Online]. [cited 2007]; Available from: URL: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2007/index
  5. Sessions J. Chronic myeloid leukemia in 2007. J Manag Care Pharm 2007; 13(8 Suppl A): 4-7.
  6. Zhang JG, Goldman JM, Cross NC. Characterization of genomic BCR-ABL breakpoints in chronic myeloid leukaemia by PCR. Br J Haematol 1995; 90(1): 138-46.
  7. Gutierrez MI, Timson G, Siraj AK, Bu R, Barbhaya S, Banavali S, et al. Single monochrome real-time RT-PCR assay for identification, quantification, and breakpoint cluster region determination of t(9;22) transcripts. J Mol Diagn 2005; 7(1): 40-7.
  8. Foroni L, Gerrard G, Nna E, Khorashad JS, Stevens D, Swela B, et al. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia. Am J Hematol 2009; 84(8): 517-22.
  9. Langabeer SE, Haslam K, Kelly J, Leahy M, Vandenberghe E. Acute lymphoblastic leukaemia with an e1a3 BCR-ABL1 fusion. Acta Haematol 2011; 126(4): 214-5.
  10. He J, Lipson D, Nahas M, Otto GA, Wang K, Knapp KM, et al. Development and analytical validation of a clinical next generation sequencing-based assay for hematolymphoid malignancies. Proceedings of the American Association for Cancer Research Annual Meeting; 2014 Apr 5-9; San Diego, CA, USA.
  11. Chen Y, Wang HW, Chen XH, Xu ZF, Qin YH, Ren FG, et al. Adult acute lymphoblastic leukemia with atypical BCR-ABL transcript e1a3: a case report and literature review. Zhonghua Xue Ye Xue Za Zhi 2013; 34(11): 965-6. [In Chinese].
  12. Yaghmaie M, Ghaffari SH, Alimoghaddam K, Ghavamzadeh A, Mousavi SA, Irvani M, et al. Frequency of BCR-ABL fusion transcript in Iranian patients with chronic myeloid leukemia. Int J Hematol Oncol Stem Cell Res 2015; 2(3): 1-5.
  13. Perego RA, Costantini M, Cornacchini G, Gargantini L, Bianchi C, Pungolino E, et al. The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia. Eur J Cancer 2000; 36(11): 1395-401.
  14. Prejzner W. Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia. Med Sci Monit 2002; 8(5): BR193-BR197.
  15. Hassan R, Ramli M, Abdullah WZ, BaBa A. Short communication One-Step Multiplex RT-PCR for detection of BCR/ABL gene in Malay patients with chronic myeloid leukaemia. Asia Pac J Mol Biol Biotechnol 2008; 16(2): 41-4.
  16. Mino C, Burgos R, Morillo SA, Santos JC, Fiallo BF, Leone PE. BCR-ABL rearrangement frequencies in chronic myeloid leukemia and acute lymphoblastic leukemia in Ecuador, South America. Cancer Genet Cytogenet 2002; 132(1): 65-7.
  17. Osman EA, Hamad K, Elmula IM, Ibrahim ME. Frequencies of BCR-ABL1 fusion transcripts among Sudanese chronic myeloid leukaemia patients. Genet Mol Biol 2010; 33(2): 229-31.
  18. Junmei Z, Fengkuan Y, Yongping S, Baijun F, Yuzhang L, Lina L, et al. Coexistence of P190 and P210 BCR/ABL transcripts in chronic myeloid leukemia blast crisis resistant to imatinib. Springerplus 2015; 4: 170.
  19. Tashfeen S, Ahmed S, Bhatti FA, Ali N. Real time polymerase chain reaction in diagnosis of chronic myeloid leukemia. J Coll Physicians Surg Pak 2014; 24(3): 190-3.
  20. Anand MS, Varma N, Varma S, Rana KS, Malhotra P. Cytogenetic & molecular analyses in adult chronic myelogenous leukaemia patients in north India. Indian J Med Res 2012; 135: 42-8.
Journal of Isfahan Medical School
Volume 34, Issue 382 - Serial Number 382
March and April 2016
Pages 515-520

Files

History

  • Receive Date: 12 November 2015
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics